NKGN.US NKGen Biotech, Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.0600 USD
Close of Nov 17, 2026
0.0020 0.2000
Market cap
USD 7.84M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NKGN.US undervalued?

Graham number

The Graham number of NKGen Biotech, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NKGen Biotech, Inc. Common Stock fundamental analysis

No fundamental analysis for NKGen Biotech, Inc. Common Stock yet.

NKGen Biotech, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NKGen Biotech, Inc. Common Stock

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed P…

Full company profile